Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462205 | 0.79 | GLS (0.48) | HRH3HRH4GLS | |
| SCHEMBL453856 | 0.75 | CYP11B1 (0.38) | L3MBTL1HRH3HRH4HRH1CYP1A2 | |
| SCHEMBL41191 | 0.71 | L3MBTL1 (0.59) | L3MBTL1HRH3HRH4HRH1LMNA | |
| SCHEMBL29830938 | 0.71 | L3MBTL1 (0.59) | L3MBTL1HRH3HRH4HRH1LMNA | |
| Bromide SCHEMBL6114859 | 0.69 | L3MBTL1 (0.57) | L3MBTL1HRH3HRH4HRH1LMNA | |
| Hydrochloric Acid SCHEMBL10884973 | 0.69 | L3MBTL1 (0.57) | L3MBTL1HRH3HRH4HRH1LMNA | |
| SCHEMBL4938201 | 0.69 | L3MBTL1 (0.57) | L3MBTL1HRH3HRH4HRH1LMNA | |
| SCHEMBL29715188 | 0.69 | L3MBTL1 (0.57) | L3MBTL1HRH3HRH4HRH1LMNA | |
| Ammonia Solution, Strong SCHEMBL6176560 | 0.69 | L3MBTL1 (0.57) | L3MBTL1HRH3HRH4HRH1LMNA | |
| SCHEMBL4938207 | 0.69 | L3MBTL1 (0.57) | L3MBTL1HRH3HRH4HRH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815863-B2 | Hydrogen bond forming fluoro ketolides for treating diseases | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2613630-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Cempra Pharmaceuticals, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2012034058-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Q6ZSR9, LSS, LCT | L3MBTL1 141/4885HRH3 4079/4885HRH4 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.